These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38666485)

  • 1. Activation and Purification of ß-Glucocerebrosidase by Exploiting its Transporter LIMP-2 - Implications for Novel Treatment Strategies in Gaucher's and Parkinson's Disease.
    Dobert JP; Bub S; Mächtel R; Januliene D; Steger L; Regensburger M; Wilfling S; Chen JX; Dejung M; Plötz S; Hehr U; Moeller A; Arnold P; Zunke F
    Adv Sci (Weinh); 2024 Jul; 11(25):e2401641. PubMed ID: 38666485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of Glucocerebrosidase Activity beyond Gaucher Disease: PSAP and LIMP-2 Dysfunctions.
    Pavan E; Peruzzo P; Cattarossi S; Bergamin N; Bordugo A; Sechi A; Scarpa M; Biasizzo J; Colucci F; Dardis A
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.
    Ambrosi G; Ghezzi C; Zangaglia R; Levandis G; Pacchetti C; Blandini F
    Neurobiol Dis; 2015 Oct; 82():235-242. PubMed ID: 26094596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal trafficking defects link Parkinson's disease with Gaucher's disease.
    Wong YC; Krainc D
    Mov Disord; 2016 Nov; 31(11):1610-1618. PubMed ID: 27619775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of GCase Activity in Cultured Cells.
    Shojima Y; Ogata J; Tsunemi T; Imai Y; Hattori N
    Methods Mol Biol; 2021; 2322():47-52. PubMed ID: 34043191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblasts from idiopathic Parkinson's disease exhibit deficiency of lysosomal glucocerebrosidase activity associated with reduced levels of the trafficking receptor LIMP2.
    Thomas R; Moloney EB; Macbain ZK; Hallett PJ; Isacson O
    Mol Brain; 2021 Jan; 14(1):16. PubMed ID: 33468204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocerebrosidase dysfunction in neurodegenerative disease.
    Brooker SM; Krainc D
    Essays Biochem; 2021 Dec; 65(7):873-883. PubMed ID: 34528667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acid ceramidase involved in pathogenic cascade leading to accumulation of α-synuclein in iPSC model of GBA1-associated Parkinson's disease.
    Kumar M; Srikanth MP; Deleidi M; Hallett PJ; Isacson O; Feldman RA
    Hum Mol Genet; 2023 May; 32(11):1888-1900. PubMed ID: 36752535
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lysosomal functions and dysfunctions: Molecular and cellular mechanisms underlying Gaucher disease and its association with Parkinson disease.
    Horowitz M; Braunstein H; Zimran A; Revel-Vilk S; Goker-Alpan O
    Adv Drug Deliv Rev; 2022 Aug; 187():114402. PubMed ID: 35764179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the complex formed by β-glucocerebrosidase and the lysosomal integral membrane protein type-2.
    Zunke F; Andresen L; Wesseler S; Groth J; Arnold P; Rothaug M; Mazzulli JR; Krainc D; Blanz J; Saftig P; Schwake M
    Proc Natl Acad Sci U S A; 2016 Apr; 113(14):3791-6. PubMed ID: 27001828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease.
    Magalhaes J; Gegg ME; Migdalska-Richards A; Doherty MK; Whitfield PD; Schapira AH
    Hum Mol Genet; 2016 Aug; 25(16):3432-3445. PubMed ID: 27378698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.
    Rubilar JC; Outeiro TF; Klein AD
    Brain; 2024 Aug; 147(8):2610-2620. PubMed ID: 38437875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel beta-glucocerebrosidase chaperone compounds identified from cell-based screening reduce pathologically accumulated glucosylsphingosine in iPS-derived neuronal cells.
    Naito Y; Sakamoto S; Kojima T; Homma M; Tanaka M; Matsui H
    SLAS Discov; 2023 Oct; 28(7):344-349. PubMed ID: 37369311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of cysteine protease cathepsin L increases the level and activity of lysosomal glucocerebrosidase.
    Kim MJ; Kim S; Reinheckel T; Krainc D
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38329128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between glucocerebrosidase mutations and Parkinson disease.
    Migdalska-Richards A; Schapira AH
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):77-90. PubMed ID: 26860875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein interacts with Glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases.
    Yap TL; Gruschus JM; Velayati A; Westbroek W; Goldin E; Moaven N; Sidransky E; Lee JC
    J Biol Chem; 2011 Aug; 286(32):28080-8. PubMed ID: 21653695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The LIMP-2/SCARB2 binding motif on acid β-glucosidase: basic and applied implications for Gaucher disease and associated neurodegenerative diseases.
    Liou B; Haffey WD; Greis KD; Grabowski GA
    J Biol Chem; 2014 Oct; 289(43):30063-74. PubMed ID: 25202012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential Binding Sites of Pharmacological Chaperone NCGC00241607 on Mutant β-Glucocerebrosidase and Its Efficacy on Patient-Derived Cell Cultures in Gaucher and Parkinson's Disease.
    Kopytova AE; Rychkov GN; Cheblokov AA; Grigor'eva EV; Nikolaev MA; Yarkova ES; Sorogina DA; Ibatullin FM; Baydakova GV; Izyumchenko AD; Bogdanova DA; Boitsov VM; Rybakov AV; Miliukhina IV; Bezrukikh VA; Salogub GN; Zakharova EY; Pchelina SN; Emelyanov AK
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting neuronal lysosomal dysfunction caused by β-glucocerebrosidase deficiency with an enzyme-based brain shuttle construct.
    Gehrlein A; Udayar V; Anastasi N; Morella ML; Ruf I; Brugger D; von der Mark S; Thoma R; Rufer A; Heer D; Pfahler N; Jochner A; Niewoehner J; Wolf L; Fueth M; Ebeling M; Villaseñor R; Zhu Y; Deen MC; Shan X; Ehsaei Z; Taylor V; Sidransky E; Vocadlo DJ; Freskgård PO; Jagasia R
    Nat Commun; 2023 Apr; 14(1):2057. PubMed ID: 37045813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson's disease.
    Williams D; Glasstetter LM; Jong TT; Chen T; Kapoor A; Zhu S; Zhu Y; Calvo R; Gehrlein A; Wong K; Hogan AN; Vocadlo DJ; Jagasia R; Marugan JJ; Sidransky E; Henderson MJ; Chen Y
    Proc Natl Acad Sci U S A; 2024 Oct; 121(42):e2406009121. PubMed ID: 39388267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.